Sanofi Matches, But Does Not Better, Amgen In OX40 Contest

Mid-stage data on amlitelimab in uncontrolled atopic dermatitis look in line with rival rocatinlimab, which is already more advanced.      

Businessman and businesswoman armwrestling at the office table, maintaining eye contact, trying to get leadership, fighting for equal rights for women, business competitors in the marketplace

Sanofi has previously stated that amlitelimab could be both a first- and a best-in-class therapy in atopic dermatitis (Also see "Sanofi Looks To Build On Dupixent Dominance With OX40L Drug" - Scrip, 27 June, 2023.). Updated data from a Phase IIb trial released last week, however, suggest that it is doubtful that either goal will be achieved by the anti-OX40-ligand antibody.

Key Takeaways
  • Phase IIb data on Sanofi’s anti-OX40-ligand antibody amlitelimab are good enough to start Phase III

For a start, the product has not yet entered Phase III trials, whereas Amgen, Inc.’s rocatinlimab, a similarly-acting agent...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By 

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

 

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.

More from R&D

Pipeline Watch: Twelve Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.